Yes, start osteoporosis therapy immediately
A patient with osteopenia and FRAX scores of 18.6% for major osteoporotic fracture and 4.8% for hip fracture meets treatment thresholds and should be started on pharmacologic therapy to prevent fractures. This patient clearly qualifies for treatment based on multiple established guidelines.
Why Treatment is Indicated
Your FRAX scores exceed the widely accepted treatment thresholds 1, 2:
- Major osteoporotic fracture risk of 18.6% exceeds the ≥20% threshold by a narrow margin, but more importantly
- Hip fracture risk of 4.8% significantly exceeds the ≥3% threshold (some guidelines use ≥4.5% for very high risk 3, 4)
The 2020 AACE/ACE guidelines explicitly state that pharmacologic therapy is strongly recommended for patients with a T-score between -1.0 and -2.5 if the FRAX 10-year probability for major osteoporotic fracture is ≥20% OR the 10-year probability of hip fracture is ≥3% 1. Note this is an "OR" statement—you only need to meet one threshold, and you exceed the hip fracture threshold.
The American College of Physicians similarly recommends that clinicians should treat osteopenic women 65 years or older who are at high risk for fracture, with treatment decisions based on fracture risk profile 2. The 2025 USPSTF guidelines support screening and treatment when fracture risk is elevated 5.
First-Line Treatment Recommendations
Start with an oral bisphosphonate (alendronate or risedronate) as first-line therapy 1, 2:
- Alendronate: 70 mg once weekly OR 10 mg daily
- Risedronate: 35 mg once weekly OR 5 mg daily
These agents have the strongest evidence for fracture reduction across all sites (hip, spine, and non-vertebral fractures), are cost-effective, and have well-established safety profiles 1, 5.
Alternative Options if Oral Bisphosphonates Are Not Appropriate:
If you cannot tolerate oral bisphosphonates (due to esophageal problems, inability to remain upright for 30 minutes, or other contraindications):
- IV bisphosphonates: Zoledronic acid 5 mg IV annually 1
- Denosumab: 60 mg subcutaneously every 6 months 1
For patients at very high fracture risk (which you approach with your hip fracture risk near 5%), consider anabolic agents like teriparatide, abaloparatide, or romosozumab as initial therapy, though this is typically reserved for those with prior fractures or T-scores ≤-3.5 1.
Essential Concurrent Measures
While starting pharmacologic therapy:
- Calcium: 1,000-1,200 mg daily (dietary plus supplemental) 6, 1
- Vitamin D: 800-1,000 IU daily (target serum level ≥20 ng/mL) 6, 1
- Weight-bearing and resistance exercise: At least twice weekly 1
- Fall prevention assessment: Particularly important given your elevated hip fracture risk 1
- Smoking cessation if applicable 1
- Limit alcohol to ≤2 drinks daily 1
Monitoring Plan
- Repeat DXA scan: Every 1-2 years initially until stable 1
- Assess treatment response: Check bone turnover markers if available
- Reassess fracture risk annually 1
Important Caveats
Do not delay treatment while optimizing calcium and vitamin D—these should be started concurrently with pharmacologic therapy, not sequentially 1.
Bisphosphonate administration requires specific instructions: Take on an empty stomach with plain water, remain upright for at least 30 minutes, and take nothing else by mouth during this time to ensure absorption and prevent esophageal irritation 6.
If you have any contraindications to bisphosphonates (severe kidney disease with GFR <30-35 mL/min, hypocalcemia, esophageal abnormalities), discuss alternative agents with your physician immediately 1.
The evidence clearly supports that treating osteopenia at your fracture risk level prevents fractures and improves quality of life, with benefits beginning within 9-18 months of treatment 7, 5.